[GFMD] Global Fellow in Medicines
Development GFMD Certification Review
Guide
**Question 1.** Which document formally defines the desired characteristics of a drug
candidate to guide its development from discovery to market?
A) Investigational New Drug (IND) application
B) Target Product Profile (TPP)
C) Clinical Study Report (CSR)
D) Summary of Product Characteristics (SmPC)
Answer: B
Explanation: The TPP outlines efficacy, safety, dosage, and other attributes that the final product
should meet, serving as a roadmap for development.
**Question 2.** In translational research, what is the primary purpose of identifying an unmet
medical need?
A) To secure funding from investors
B) To prioritize lead compound selection that addresses a gap in therapy
C) To comply with regulatory filing deadlines
D) To design marketing strategies early on
Answer: B
Explanation: Recognizing unmet needs ensures that the chosen lead compound targets a
disease area lacking effective treatments, aligning scientific effort with clinical relevance.
**Question 3.** Which phase of clinical trials is primarily concerned with establishing the
maximum tolerated dose (MTD) and dose‑limiting toxicities?
A) Phase I
B) Phase II
C) Phase III
, [GFMD] Global Fellow in Medicines
Development GFMD Certification Review
Guide
D) Phase IV
Answer: A
Explanation: Phase I trials are first‑in‑human studies that assess safety, tolerability,
pharmacokinetics, and determine the MTD.
**Question 4.** The Declaration of Helsinki is a cornerstone for which aspect of drug
development?
A) Statistical analysis plans
B) Ethical conduct of human research
C) Manufacturing process validation
D) Post‑marketing surveillance reporting
Answer: B
Explanation: The Declaration of Helsinki provides ethical principles for conducting medical
research involving human subjects.
**Question 5.** Which regulatory agency is responsible for the Centralized Procedure for drug
approval throughout the European Union?
A) FDA
B) EMA
C) PMDA
D) Health Canada
Answer: B
Explanation: The European Medicines Agency (EMA) oversees the centralized marketing
authorization, granting a single EU-wide approval.
, [GFMD] Global Fellow in Medicines
Development GFMD Certification Review
Guide
**Question 6.** In pharmacovigilance, a Serious Adverse Event (SAE) is defined as an event that
results in any of the following EXCEPT:
A) Death
B) Life‑threatening condition
C) Temporary mild headache
D) Hospitalization
Answer: C
Explanation: A mild headache does not meet the regulatory criteria for seriousness; SAEs
involve death, life‑threatening events, hospitalization, disability, or congenital anomaly.
**Question 7.** Which statistical concept reflects the probability of incorrectly rejecting the
null hypothesis?
A) Power
B) Confidence interval
C) p‑value
D) Effect size
Answer: C
Explanation: The p‑value quantifies the chance of observing the data, or more extreme, if the
null hypothesis is true; a low p‑value leads to rejection.
**Question 8.** CDISC standards are primarily used to:
A) Design clinical trial protocols
B) Harmonize electronic data capture and data submission formats
C) Conduct meta‑analyses of published literature
D) Perform health economic modeling
, [GFMD] Global Fellow in Medicines
Development GFMD Certification Review
Guide
Answer: B
Explanation: CDISC provides standardized data models (e.g., SDTM, ADaM) facilitating
consistent data collection, sharing, and regulatory submission.
**Question 9.** Real‑World Evidence (RWE) differs from randomized controlled trial (RCT) data
because RWE is derived from:
A) Laboratory animal studies
B) Controlled clinical environments
C) Routine clinical practice and observational sources
D) In silico molecular modeling
Answer: C
Explanation: RWE utilizes data from electronic health records, registries, claims, and other
real‑world sources outside the controlled trial setting.
**Question 10.** Quality‑adjusted life years (QALYs) combine which two elements to assess
health outcomes?
A) Cost and market share
B) Survival time and quality of life weighting
C) Dose intensity and adverse event frequency
D) Regulatory compliance and manufacturing cost
Answer: B
Explanation: QALYs multiply the length of time spent in a health state by a utility value
representing quality of life, enabling cost‑effectiveness comparisons.
**Question 11.** Which of the following is NOT a typical component of a Clinical Development
Plan (CDP)?
Development GFMD Certification Review
Guide
**Question 1.** Which document formally defines the desired characteristics of a drug
candidate to guide its development from discovery to market?
A) Investigational New Drug (IND) application
B) Target Product Profile (TPP)
C) Clinical Study Report (CSR)
D) Summary of Product Characteristics (SmPC)
Answer: B
Explanation: The TPP outlines efficacy, safety, dosage, and other attributes that the final product
should meet, serving as a roadmap for development.
**Question 2.** In translational research, what is the primary purpose of identifying an unmet
medical need?
A) To secure funding from investors
B) To prioritize lead compound selection that addresses a gap in therapy
C) To comply with regulatory filing deadlines
D) To design marketing strategies early on
Answer: B
Explanation: Recognizing unmet needs ensures that the chosen lead compound targets a
disease area lacking effective treatments, aligning scientific effort with clinical relevance.
**Question 3.** Which phase of clinical trials is primarily concerned with establishing the
maximum tolerated dose (MTD) and dose‑limiting toxicities?
A) Phase I
B) Phase II
C) Phase III
, [GFMD] Global Fellow in Medicines
Development GFMD Certification Review
Guide
D) Phase IV
Answer: A
Explanation: Phase I trials are first‑in‑human studies that assess safety, tolerability,
pharmacokinetics, and determine the MTD.
**Question 4.** The Declaration of Helsinki is a cornerstone for which aspect of drug
development?
A) Statistical analysis plans
B) Ethical conduct of human research
C) Manufacturing process validation
D) Post‑marketing surveillance reporting
Answer: B
Explanation: The Declaration of Helsinki provides ethical principles for conducting medical
research involving human subjects.
**Question 5.** Which regulatory agency is responsible for the Centralized Procedure for drug
approval throughout the European Union?
A) FDA
B) EMA
C) PMDA
D) Health Canada
Answer: B
Explanation: The European Medicines Agency (EMA) oversees the centralized marketing
authorization, granting a single EU-wide approval.
, [GFMD] Global Fellow in Medicines
Development GFMD Certification Review
Guide
**Question 6.** In pharmacovigilance, a Serious Adverse Event (SAE) is defined as an event that
results in any of the following EXCEPT:
A) Death
B) Life‑threatening condition
C) Temporary mild headache
D) Hospitalization
Answer: C
Explanation: A mild headache does not meet the regulatory criteria for seriousness; SAEs
involve death, life‑threatening events, hospitalization, disability, or congenital anomaly.
**Question 7.** Which statistical concept reflects the probability of incorrectly rejecting the
null hypothesis?
A) Power
B) Confidence interval
C) p‑value
D) Effect size
Answer: C
Explanation: The p‑value quantifies the chance of observing the data, or more extreme, if the
null hypothesis is true; a low p‑value leads to rejection.
**Question 8.** CDISC standards are primarily used to:
A) Design clinical trial protocols
B) Harmonize electronic data capture and data submission formats
C) Conduct meta‑analyses of published literature
D) Perform health economic modeling
, [GFMD] Global Fellow in Medicines
Development GFMD Certification Review
Guide
Answer: B
Explanation: CDISC provides standardized data models (e.g., SDTM, ADaM) facilitating
consistent data collection, sharing, and regulatory submission.
**Question 9.** Real‑World Evidence (RWE) differs from randomized controlled trial (RCT) data
because RWE is derived from:
A) Laboratory animal studies
B) Controlled clinical environments
C) Routine clinical practice and observational sources
D) In silico molecular modeling
Answer: C
Explanation: RWE utilizes data from electronic health records, registries, claims, and other
real‑world sources outside the controlled trial setting.
**Question 10.** Quality‑adjusted life years (QALYs) combine which two elements to assess
health outcomes?
A) Cost and market share
B) Survival time and quality of life weighting
C) Dose intensity and adverse event frequency
D) Regulatory compliance and manufacturing cost
Answer: B
Explanation: QALYs multiply the length of time spent in a health state by a utility value
representing quality of life, enabling cost‑effectiveness comparisons.
**Question 11.** Which of the following is NOT a typical component of a Clinical Development
Plan (CDP)?
